Log in or Sign up for Free to view tailored content for your specialty!
Alzheimer’s Disease/Dementia News
Brexpiprazole improves agitation in patients with Alzheimer’s dementia over 12 weeks
Treatment with brexpiprazole 2 mg or 3 mg resulted in significant reduction in agitation over 12 weeks compared with placebo in adults with Alzheimer’s dementia, according to research published in JAMA Neurology.
$10M research initiative will fund research on neuroinflammation
The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.
Log in or Sign up for Free to view tailored content for your specialty!
Imeka receives investment from ADDF to develop novel biomarkers for Alzheimer’s disease
A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to accelerate development of novel biomarkers for Alzheimer’s disease and related dementias.
Medications to treat agitation in dementia have no significant effect on cognition
A systematic review and meta-analysis of trial literature found that medications investigated for treatment of agitation in dementia demonstrated no significant effect on cognition, according to a poster presentation at CTAD.
Phase 2/3 trial of Alzheimer’s therapy permitted to continue by monitoring board
Annovis Bio has been permitted by the Data and Safety Monitoring Board to continue its phase 2/3 trial of buntanetap, an oral protein inhibitor for moderate to mild Alzheimer’s disease, according to a company release.
COVID-19 mitigating factor in self-perceived cognitive decline for older adults
In a cohort of older adults, the COVID-19 pandemic was a mitigating factor in self-perceived cognitive decline, the presence of which indicated a higher risk factor for worsening cognitive function in the year following the pandemic.
Association strong between MCI, related comorbidities, but decreases with age
For early detection of Alzheimer’s disease in older adults, comorbidities remained strongly associated with mild cognitive impairment, but prediction decreased with age, according to a poster presentation at CTAD.
Machine learning model most accurately predicts levels of cognitive impairment
An artificial intelligence-based machine learning model that diagnosed cognitive impairment in Alzheimer’s disease extracted information more accurately than standard screening or human analysis, according to a poster presentation at CTAD.
Neurocognitive composite accurately detected symptom worsening in Alzheimer’s
Time-dependent worsening of cognition and function among a cohort of individuals with biomarker-proven Alzheimer’s disease or dementia was accurately detected by a composite neurocognitive measure.
Eye-tracking AI device aids in detection of dementia risk in underrepresented group
A novel, eye-tracking metrics device aided in the detection of dementia risk in a small population of Colombian individuals with differing levels of education, according to a poster presented at CTAD.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read